Ochre Bio
Private Company
Biotechnology Research
Oxford
11-50 employees
Founded Sep 2019
About Ochre Bio
Ochre Bio is a biotechnology firm dedicated to developing RNA therapeutics for chronic liver diseases. The company utilizes its proprietary AI-driven discovery platforms and extensive human liver datasets to identify and validate novel drug targets. Ochre Bio collaborates with major pharmaceutical companies to accelerate research and development of regenerative medicines.
Company Classification
Customer Types
B2B
Business Models
ProductsServicesLicensingData Monetization
Product & Service Types
RNA TherapeuticsAI Drug Discovery PlatformsGenomic Data Licensing
Funding
Total Funding
$39.75M
No. of Funding Rounds
4
Customers
| Customer | Success Story | Source |
|---|---|---|
| Provided a $1 billion funding partnership and entered a multi‑target, multi‑year collaboration to leverage Ochre Bio’s RNA‑therapy platform for identifying and validating regenerative targets for metabolic dysfunction‑associated steatohepatitis (MASH) and other chronic liver diseases. | ||
| Entered a multi-year data licence agreement to access Ochre Bio’s computational biology, cellular, and human organ platforms, generating extensive human liver datasets to improve AI models and drug target selection for liver disease therapies. |
Sign up to Ethos to access the full customer list, plus detailed competitor and product analysis.
Sign up to Ethos